氯沙坦治疗肾移植后红细胞增多症

Effect of Losartan on Postrenal Transplant Erythrocytosis

目的:观察氯沙坦治疗肾移植后红细胞增多症的疗效及安全性。方法:自2000年1月～2002年10月使用氯沙坦治疗肾移植后红细胞增多症18例。结果:服用氯沙坦1个月后,其过高的红细胞压积(HCT)明显下降,2个月后有12例HCT降为正常,3个月后共有16例HCT恢复正常,另2例在氯沙坦治疗4个月后降为正常,此后HCT稳定在正常范围内。2例停药3个月后红细胞增多症复发,但再次服用氯沙坦效果良好。有12例已停止服用氯沙坦6个月以上,至今HCT正常。所有患者无贫血及其它不良反应。结论:氯沙坦是一种治疗肾移植后红细胞增多症安全、有效的药物。

Objective: To determine the safety and efficacy of losartan, in treating patients with postrenal transplant erythrocytosis (PTE). Method: 18 renal ransplantation recipients complicating erythrocytosis were treated with losartan between January, 2000 and October 2002. Result: A significant decline of hematocrit was observed one month after the treatment and returned to normal in 16 cases within 3 months. The other 2 patients had normal hematocrit after treatment for 4 months. The hematocrit had been stabilized and no patient became anemia. Erythrocytosis recurred in 2 cases after discontinued losartan for 3 months, but satisfactory therapeatic response was observed again after the resumed use of losartan. 12 cases had discontinued losartan in at least 6 months with no recurrence of erythrocytosis. No side effects were noted in all patients. Conclusion: Losartan is safe and effective for the treatment of postrenal transplant erythrocytosis.